Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma.
Katzel JA et al. Anticancer Drugs. 2015 Jun 23. [Epub ahead of print].
Haematalogical cancer: Elotuzumab reduces risk of multiple myeloma progression.
[No authors listed]. Nat Rev Clin Oncol. 2015 Jun 23. doi: 10.1038/nrclinonc.2015.115. [Epub ahead of print].
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Sborov DW et al. Br J Haematol. 2015 Jun 8. doi: 10.1111/bjh.13527. [Epub ahead of print].
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG et al. Expert Rev Anticancer Ther. 2015 Jul;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S et al. N Engl J Med. 2015 Jun 2. [Epub ahead of print].
Phase I/II study of weekly PM00104 (Zalypsis® ) in patients with relapsed/refractory multiple myeloma.
Ocio EM et al. Br J Haematol. 2015 Jun 2. doi: 10.1111/bjh.13515. [Epub ahead of print].